Peter Steinberger
Overview
Explore the profile of Peter Steinberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
2601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voogd L, van den Broek R, van Wolfswinkel M, Franken K, Ruibal P, Jespers W, et al.
J Immunol
. 2025 Mar;
PMID: 40085431
The virtually monomorphic antigen presentation molecule HLA-E can present self- and non-self peptides to the NKG2A/CD94 co-receptor inhibitory complex expressed on natural killer (NK) cells and to T cell receptors...
2.
Tajti G, Gebetsberger L, Pamlitschka G, Aigner-Radakovics K, Leitner J, Steinberger P, et al.
Front Immunol
. 2025 Feb;
16:1460089.
PMID: 39963132
Monocytes and macrophages, as important constituents of the innate immune system, are equipped with multiple Toll-like-receptors (TLRs) to recognize invading pathogens, such as SARS-CoV-2, and mount an antiviral response. Nevertheless,...
3.
Muhlgrabner V, Plach A, Holler J, Leitner J, Steinberger P, Dupre L, et al.
Methods Cell Biol
. 2025 Feb;
193:127-154.
PMID: 39919839
Understanding human T-cell antigen recognition in health and disease is becoming increasingly instrumental for monitoring T-cell responses to pathogen challenge and for the rational design of T-cell-based therapies targeting cancer,...
4.
Arifin M, Leitner J, Egan D, Waidhofer-Sollner P, Kolch W, Zhernovkov V, et al.
iScience
. 2025 Jan;
28(2):111773.
PMID: 39877899
[This corrects the article DOI: 10.1016/j.isci.2024.110253.].
5.
Adachi Y, Terakura S, Osaki M, Okuno Y, Sato Y, Sagou K, et al.
Nat Commun
. 2024 Dec;
15(1):10376.
PMID: 39658572
Chimeric antigen receptor (CAR) T cell is a promising therapy for cancer, but factors that enhance the efficacy of CAR T cell remain elusive. Here we perform a genome-wide CRISPR...
6.
Leitner J, Aigner-Radakovics K, Steinberger P
FASEB J
. 2024 Nov;
38(22):e70190.
PMID: 39560030
LAG-3 is a member of the immunoglobulin superfamily expressed on activated T cells, but also on other immune cells. It has significant homology to CD4. Both molecules have four extracellular...
7.
Jahan F, Koski J, Schenkwein D, Yla-Herttuala S, Goos H, Huuskonen S, et al.
Front Mol Med
. 2024 Aug;
3:1070384.
PMID: 39086686
T cells that are genetically modified with chimeric antigen receptor (CAR) hold promise for immunotherapy of cancer. Currently, there are intense efforts to improve the safety and efficacy of CAR...
8.
Gil-Cantero S, Iorio F, Unalan I, Kurtuldu F, Kunig S, Wenhardt C, et al.
Biomater Sci
. 2024 Jul;
12(18):4695-4712.
PMID: 39082440
Tendinopathies are a major worldwide clinical problem. The development of tendon biomimetic scaffolds is considered a promising, therapeutic approach. However, to be clinically effective, scaffolds should avoid immunological recognition. It...
9.
Tobias J, Steinberger P, Wilkinson J, Klais G, Kundi M, Wiedermann U
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066432
Immunity against respiratory pathogens is often short-term, and, consequently, there is an unmet need for the effective prevention of such infections. One such infectious disease is coronavirus disease 19 (COVID-19),...
10.
Khopanlert W, Choochuen P, Maneechai K, Jangphattananont N, Ung S, Okuno S, et al.
Mol Ther Oncol
. 2024 Jul;
32(3):200837.
PMID: 39050989
CD19 chimeric antigen receptor T (CD19CAR-T) cells have achieved promising outcomes in relapsed/refractory B cell malignancies. However, recurrences occur due to the loss of CAR-T cell persistence. We developed dual...